• If you are wondering whether Summit Therapeutics at US$19.68 is starting to look expensive or still offers value, you are not alone.
• The stock has had a strong run, with returns of 12.8% over the last 7 days, 12.0% over the last 30 days, 12.3% year to date, 8.3% over 1 year and about 3x over 3 years. The 5 year return sits at 271.3%.
• Recent attention on Summit Therapeutics has been driven by ongoing interest in its pipeline and partnerships within the pharmaceuticals and biotech space. This context helps explain why the share price has been active and why investors are increasingly focused on what a fair value range might look like.
• On our checklist of six valuation tests, Summit Therapeutics is assessed as undervalued on 2, giving it a 2/6 valuation score. Next, we will compare what different valuation approaches say about the stock before finishing with a more complete way to think about what it is really worth over time.

Summit Therapeutics scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Summit Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of the cash a company might generate in the future, then discounts those cash flows back to today to arrive at an estimate of what the business could be worth now.

For Summit Therapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is a loss of $270.172 million. Analysts provide inputs out to 2028, and Simply Wall St extrapolates further. Within those projections, free cash flow is estimated at $2,829.051 million in 2030, with a path that includes both negative and positive annual figures as the business is modeled to scale.

Pulling all of those projected cash flows together and discounting them back to today gives an estimated intrinsic value of about $218.09 per share. Compared with the current share price of $19.68, the DCF output implies the stock is around 91.0% undervalued on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Summit Therapeutics is undervalued by 91.0%. Track this in your watchlist or portfolio, or discover 881 more undervalued stocks based on cash flows.

Approach 2: Summit Therapeutics Price vs Book

Price to Book, or P/B, is often used for companies where earnings are limited or volatile, because it compares the share price to the accounting value of net assets rather than relying on profits. For profitable businesses, investors usually look for a P/B level that reflects both growth expectations and risk, with higher growth and lower perceived risk often supporting a higher multiple.

Summit Therapeutics currently trades on a P/B ratio of 78.93x. That sits well above the Biotechs industry average P/B of 2.70x and also above the peer group average of 8.63x. On those simple comparisons, the shares trade at a much higher level than many companies in the same space.

Simply Wall St’s Fair Ratio is a proprietary estimate of what P/B might be reasonable for Summit Therapeutics after accounting for factors like earnings growth, profit margins, industry, market cap and company specific risks. This tends to give a more tailored view than a straight comparison with peers or the broad industry, which can ignore important differences between businesses. In this case, the Fair Ratio cannot be calculated from the available data, so it is not possible to formally compare it with the current 78.93x P/B to reach a firm conclusion.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1445 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Summit Therapeutics Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives.

A Narrative is simply your story about a company, written in numbers, where you set your view of fair value and your expectations for future revenue, earnings and margins, then see how that translates into a price range that makes sense to you.

On Simply Wall St, Narratives live on the Community page and help you connect the story you believe about Summit Therapeutics to a financial forecast and then to a fair value. You can compare this to today’s US$19.68 share price to decide whether the stock looks attractive, fully priced or expensive for your own assumptions.

Because Narratives update automatically when new information such as news or earnings is added, your view can stay current without you rebuilding a full model each time. You can also compare different Summit Therapeutics Narratives side by side. For example, one investor might use very optimistic growth and margin assumptions that support a much higher fair value, while another might use more cautious inputs that lead to a much lower figure.

Do you think there's more to the story for Summit Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.